Friday, December 30, 2016
Thursday, December 29, 2016
Thursday, December 22, 2016
Wednesday, December 14, 2016
Thursday, December 8, 2016
Thursday, December 1, 2016
Thursday, November 24, 2016
Wednesday, November 9, 2016
Call For Paper
2:24 AM
No comments
Bentham Science Publishers would like to invite you to submit your research paper for publishing in the Journal of
Current Drug Metabolism
Current Drug Metabolism
Wednesday, November 2, 2016
Highlighted Article: The Role of Drug Transporters in the Pharmacokinetics of Antibiotics
10:47 PM
No comments
The Role of Drug Transporters in the Pharmacokinetics of Antibiotics
Author(s):
Wen Jin Hua, Wei Xiao Hua, Zhou Jian, Peng Hong Wei, Lu Yan Ni, Li Yu Hua, Cao Duan Wen, Zhou Ying and Cao Li Pages 799 - 805 ( 7 )
Abstract:
Background: Various transporters, including efflux transporters and uptake transporters, play an important role in the pharmacokinetics of drugs. Currently, studies suggest that several antibiotics also serve as substrates for transporters. In addition, these antibiotics are usually combined with other drugs to treat diseases, more effectively. Therefore, it is necessary to focus on the role of transporters in pharmacokinetics and drug-drug interactions of antibiotics.
Methods: This review summarizes the findings of recent studies as well as information retrieved from several databases (until June 2015): ISI Web of KnowledgeSM (ISI WoK), SciFinder (Caplus, Medline, Registry, Casreact, Chrmlist, and Chemcasts) and PubMed (indexed for Medline).
Results: The present review provides useful information for the study of transporters in the pharmacokinetics and drug-drug interactions of antibiotics, and should assist researchers investigating these topics.
Conclusion: The drug transporters mediate intestinal absorption, hepatic uptake, and kidney or biliary excretion. It is necessary to focus on drug-drug interactions when these antibiotics are combined with other chemical substances that are also the substrates for transporters.
Keywords:
Antibiotics, BCRP, drug transporters, MRP, OATP, P-gp.
Affiliation:
Department of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Graphical Abstract:
For More Information Please Visit Our Website Current Drug Metabolism
Wednesday, October 26, 2016
Most Cited Article: Prodrugs of Quercetin and Resveratrol: A Strategy Under Development
12:37 AM
No comments
Prodrugs of Quercetin
and Resveratrol: A Strategy Under Development
Author(s):
Lucia Biasutto and Mario ZorattiPages 77-95
(19)
Abstract:
The biochemical activities of plant flavonoids and stilbenoids point to many health-related applications, hampered however by a low bioavailability associated with rapid metabolic modification. A possible approach to overcome this obstacle is the development of prodrugs. In this review we provide some background information and summarize the efforts made so far to obtain suitable precursors of the two best known model polyphenols belonging to the classes just mentioned, quercetin and resveratrol. Prodrug design needs to take into account two key aspects: the nature of the chemical bond linking the core molecule to the protecting substituent, and the substituent itself, which can impart desirable physico-chemical properties. Only recently a systematic study of the several possible combinations has begun. Most bond systems tested so far appear to be either too stable or too unstable under physiological conditions. A range of substituent moieties is available, allowing the modulation of properties such as water solubility and the ability to permeate biomembranes. Work so far has been largely performed in vitro, and more in vivo experiments are definitely needed for a reliable assessment of the potentialities of the classes of prodrugs produced so far and of those still awaiting creation.
Keywords:
Absorption, bioavailability, metabolism,
prodrugs, quercetin, resveratrol.
Affiliation:
CNR Institute of Neurosciences, Viale G.
Colombo 3, 35121 Padova, Italy
Wednesday, October 19, 2016
Wednesday, October 5, 2016
New Issue ::: Current Drug Metabolism, 17 Issue 8
11:52 PM
No comments
Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism and disposition. The journal serves as an international forum for the publication of timely reviews and guest edited issues in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.
Articles from the journal Current Drug Metabolism, Volume 17 Issue 8:
- Editorial (Thematic Issue: Nanoparticles for Brain and Tumor Targeting Delivery)
- Shaping Tumor Microenvironment for Improving Nanoparticle Delivery
- Recent Developments of Magnetic Nanoparticles for Theranostics of Brain Tumor
- Delivery of Nanoparticles for Treatment of Brain Tumor
- Current Status and Future Directions of Nanoparticulate Strategy for Cancer Immunotherapy
- Actively Targeted Nanoparticles for Drug Delivery to Tumor
- Influence of Tumor Microenvironment on the Distribution and Elimination of Nano-formulations
- The Role of Drug Transporters in the Pharmacokinetics of Antibiotics
- P-gp Inhibition-Based Strategies for Modulating Pharmacokinetics of Anticancer Drugs: An Update
- Salusins in Hypertension and Related Cardiovascular Diseases
For details on the articles, please visit this link :: http://bit.ly/2drIYuT
courtesy by https://benthamsciencepublishers.wordpress.com/2016/10/01/new-issue-current-drug-metabolism-17-issue-8/
Current Drug Metabolism, 17 Issue 6
3:32 AM
No comments
Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism and disposition. The journal serves as an international forum for the publication of timely reviews and guest edited issues in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments. The journal covers the following areas:
In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; bioactivation, recent developments for the identification of drug metabolites, adducts and preclinical and clinical summaries of marketed drugs.
Articles from the journal in Current Drug Metabolism, 17 Issue 6
- A Comparison of Non-Human Primate Cytochrome P450 2D Members and the Implication in Drug Discovery
- Sulfotransferase 1A1 as a Biomarker for Susceptibility to Carcinogenesis: From Molecular Genetics to the Role of Dietary Flavonoids
- Thiopurine Biotransformation and Pharmacological Effects: Contribution of Oxidative Stress
- Pharmacological Effects of RAAS Blockade in Ischemic Nephropathy
- Effects of High Altitude Exposure on Physiology and Pharmacokinetics
- Genomic Variations Affecting Biological Effects of Statins
- Valproic Acid Metabolism and its Consequences on Sexual Functions
- Emerging Potential of Natural Products as an Alternative Strategy to Pharmacological Agents Used Against Metabolic Disorders
- Can Dietary Polyphenols Prevent the Formation of Toxic Compounds from Maillard Reaction?
- Medication-Induced Nephrotoxicity in Older Patients
For details on the articles, please visit this link :: http://bit.ly/23hETZs
courtesy by : https://benthamsciencepublishers.wordpress.com/2016/07/06/new-issue-current-drug-metabolism-17-issue-6/
Highlighted Article Flyer for the journal “Current Drug Metabolism” Volume 17, Number 5
3:32 AM
No comments
courtesy by : https://benthamsciencepublishers.wordpress.com/2016/06/28/highlighted-article-flyer-for-the-journal-current-drug-metabolism-2/
Highlighted Article Flyer for the journal “Current Drug Metabolism”
3:31 AM
No comments
courtesy by : https://benthamsciencepublishers.wordpress.com/2016/06/24/highlighted-article-flyer-for-the-journal-current-drug-metabolism/
Current Drug Metabolism’s newly published issue
3:29 AM
No comments
Articles from the journal Current Drug Metabolism, 16 Issue 2
Article: Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication
Author(s): Xiaojing Tang and Shuqing Chen
Article: Evidence-Based Choice of P2Y12 Inhibitors in End Stage Renal Disease Patients: A Mini-Review
Author(s): Yassine Bouatou, Caroline Flora Samer, Pierre Fontana, Youssef Daali and Jules Desmeules
Article: Physical and Metabolic Integrity of the Blood-Brain Barrier in HIV Infection: A Special Focus on Intercellular Junctions, Influx and Efflux Transporters and Metabolizing Enzymes
Author(s): Ramzi Shawahna
Article: Interaction of Isoflavones with the BCRP/ABCG2 Drug Transporter
Author(s): Kristin M. Bircsak and Lauren M. Aleksunes
Article: Novel Atypical Antipsychotics: Metabolism and Therapeutic Drug Monitoring (TDM)
Author(s): Roberto Mandrioli, Michele Protti and Laura Mercolini
Article: Polycation-Based Ternary Gene Delivery System
Author(s): Shuai Liu and Tianying Guo
For details, please visit: http://bit.ly/1qUXoAe
courtesy by: https://benthamsciencepublishers.wordpress.com/2015/08/17/current-drug-metabolisms-newly-published-issue/
Wednesday, July 27, 2016
Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process
4:41 AM
No comments
Author(s):
Kelly E. Caudle, Teri E. Klein, James M. Hoffman, Daniel J. Muller, Michelle Whirl-Carrillo, Li Gong, Ellen M. McDonagh, Katrin Sangkuhl, Caroline F. Thorn, Matthias Schwab, Jose A.G. Agundez, Robert R. Freimuth, Vojtech Huser, Ming Ta Michael Lee, Otito F. Iwuchukwu, Kristine R. Crews, Stuart A. Scott, Mia Wadelius, Jesse J. Swen, Rachel F. Tyndale, C. Michael Stein, Dan Roden, Mary V. Relling, Marc S. Williams and Samuel G. JohnsonPages 209-217 (9)
Abstract:
The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes genotype-based drug guidelines to help clinicians understand how available genetic test results could be used to optimize drug therapy. CPIC has focused initially on well-known examples of pharmacogenomic associations that have been implemented in selected clinical settings, publishing nine to date. Each CPIC guideline adheres to a standardized format and includes a standard system for grading levels of evidence linking genotypes to phenotypes and assigning a level of strength to each prescribing recommendation. CPIC guidelines contain the necessary information to help clinicians translate patient-specific diplotypes for each gene into clinical phenotypes or drug dosing groups. This paper reviews the development process of the CPIC guidelines and compares this process to the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines.
Keywords:
Clinical practice guideline, guideline, pharmacogenetics, pharmacogenomics.
Affiliation:
262 Danny Thomas Place MS: 313, Memphis, TN 38105, USA.
Read Full-Text article
A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?
4:40 AM
No comments
Author(s):
Lorena Baietto, Silvia Corcione, Giovanni Pacini, Giovanni Di Perri, Antonio D’Avolio and Francesco Giuseppe De RosaPages 581-598 (18)
Abstract:
Drug bioavailability may vary greatly amongst individuals, affecting both efficacy and toxicity: in humans, genetic variations account for a relevant proportion of such variability. In the last decade the use of pharmacogenetics in clinical practice, as a tool to individualize treatment, has shown a different degree of diffusion in various clinical fields.
In the field of infectious diseases, several studies identified a great number of associations between host genetic polymorphisms and responses to antiretroviral therapy. For example, in patients treated with abacavir the screening for HLA-B*5701 before starting treatment is routine clinical practice and standard of care for all patients; efavirenz plasma levels are influenced by single nucleotide polymorphism (SNP) CYP2B6-516G>T (rs3745274). Regarding antibiotics, many studies investigated drug transporters involved in antibiotic bioavailability, especially for fluoroquinolones, cephalosporins, and antituberculars. To date, few data are available about pharmacogenetics of recently developed antibiotics such as tigecycline, daptomycin or linezolid. Considering the effect of SNPs in gene coding for proteins involved in antibiotics bioavailability, few data have been published.
Increasing knowledge in the field of antibiotic pharmacogenetics could be useful to explain the high drug inter-patients variability and to individualize therapy. In this paper we reported an overview of pharmacokinetics, pharmacodynamics, and pharmacogenetics of antibiotics to underline the importance of an integrated approach in choosing the right dosage in clinical practice.
Keywords:
Metabolism, pharmacology, pharmacogenomic, single nucleotide polymorphism (SNP), tailored therapy, therapeutic drug monitoring (TDM), transporter, treatment.
Affiliation:
Department of Medical Sciences, University of Turin, Infectious Diseases at Amedeo di Savoia Hospital, Corso Svizzera 164, 10149. Turin, Italy.
Read Full-Text article
Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide
4:39 AM
No comments
Author(s):
Mario Cozzolino, Felix Funk, Viatcheslav Rakov, Olivier Phan and Isaac TeitelbaumPages 953-965 (13)
Abstract:
Sucroferric oxyhydroxide (VELPHORO®) is a polynuclear iron-based phosphate binder recently approved for the treatment of hyperphosphataemia in patients with chronic kidney disease (CKD). As a number of the available phosphate binders do not provide the optimal combination of good efficacy, adequate tolerability and low pill burden, sucroferric oxyhydroxide constitutes a promising alternative. Among the attributes of an ideal phosphate binder is minimal absorption and, hence, low risk of systemic toxicity. Accordingly, the iron-releasing properties and absorption, distribution, metabolism and excretion (ADME) profile of sucroferric oxyhydroxide, as well as the possibility of iron accumulation and toxicity, were investigated in a series of preclinical studies. The effect of sucroferric oxyhydroxide on the progression of vascular calcification was also investigated. Sucroferric oxyhydroxide exhibited a high phosphate-binding capacity and low iron-releasing properties across the physiological pH range found in the gastrointestinal tract. In the ADME studies, uptake of 59Fe-radiolabelled sucroferric oxyhydroxide was low in rats and dogs (<1% from a 50 mg Fe/kg bodyweight dose), with the majority of absorbed iron located in red blood cells. Long-term (up to 2 years) administration of sucroferric oxyhydroxide in rats and dogs was associated with modest increases in tissue iron levels and no iron toxicity. Moreoever, in uraemic rats, sucroferric oxyhydroxide was associated with reduced progression of vascular calcification compared with calcium carbonate. In conclusion, sucroferric oxyhydroxide offers a new option for the treatment of hyperphosphataemia, with a high phosphate-binding capacity, minimal iron release, and low potential for iron accumulation and toxicity.
Keywords:
Chronic kidney disease (CKD), dialysis, hyperphosphataemia, phosphate, phosphate binder, preclinical, sucroferric oxyhydroxide.
Affiliation:
Department of Health Sciences, University of Milan, Renal Division, San Paolo Hospital, Via A. Di Rudinì, 8 20142 Milan, Italy.
Read Full-Text article
Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
4:39 AM
No comments
Author(s):
Derek W. Edwardson, Rashmi Narendrula, Simon Chewchuk, Kyle Mispel-Beyer, Jonathan P.J. Mapletoft and Amadeo M. ParissentiPages 412-426 (15)
Abstract:
Many clinical studies involving anti-tumor agents neglect to consider how these agents are metabolized within the host and whether the creation of specific metabolites alters drug therapeutic properties or toxic side effects. However, this is not the case for the anthracycline class of chemotherapy drugs. This review describes the various enzymes involved in the one electron (semi-quinone) or two electron (hydroxylation) reduction of anthracyclines, or in their reductive deglycosidation into deoxyaglycones. The effects of these reductions on drug antitumor efficacy and toxic side effects are also discussed. Current evidence suggests that the one electron reduction of anthracyclines augments both their tumor toxicity and their toxicity towards the host, in particular their cardiotoxicity. In contrast, the two electron reduction (hydroxylation) of anthracyclines strongly reduces their ability to kill tumor cells, while augmenting cardiotoxicity through their accumulation within cardiomyocytes and their direct effects on excitation/contraction coupling within the myocytes. The reductive deglycosidation of anthracyclines appears to inactivate the drug and only occurs under rare, anaerobic conditions. This knowledge has resulted in the identification of important new approaches to improve the therapeutic index of anthracyclines, in particular by inhibiting their cardiotoxocity. The true utility of these approaches in the management of cancer patients undergoing anthracycline-based chemotherapy remains unclear, although one such agent (the iron chelator dexrazoxane) has recently been approved for clinical use.
Keywords:
Anthracyclines, anti-tumor effects, cardiotoxicity, deoxyaglycone, hydroxylation, metabolites, optimization, semi-quinone, therapeutic index.
Affiliation:
Dept. of Chemistry and Biochemistry, Laurentian University, 935 Ramsey Lake Road, Sudbury, ON P3E 2C6, Canada.
Read Full-Text article
Digestive Enzyme Supplementation in Gastrointestinal Diseases
4:38 AM
No comments
Author(s):
Gianluca Ianiro, Silvia Pecere, Valentina Giorgio, Antonio Gasbarrini and Giovanni CammarotaPages 187-193 (7)
Abstract:
Background: Digestive enzymes are able to break down proteins and carbohydrates and lipids, and their supplementation may play a role in the management of digestive disorders, from lactose intolerance to cystic fibrosis. To date, several formulations of digestive enzymes are available on the market, being different each other in terms of enzyme type, source and origin, and dosage.
Methods: This review, performed through a non-systematic search of the available literature, will provide an overview of the current knowledge of digestive enzyme supplementation in gastrointestinal disorders, discussion of the use of pancreatic enzymes, lactase ( -galactosidase) and conjugated bile acids, and also exploring the future perspective of digestive enzyme supplementation.
Results: Currently, the animal-derived enzymes represent an established standard of care, however the growing study of plant-based and microbe-derived enzymes offers great promise in the advancement of digestive enzyme therapy.
Conclusion: New frontiers of enzyme replacement are being evaluated also in the treatment of diseases not specifically related to enzyme deficiency, whereas the combination of different enzymes might constitute an intriguing therapeutic option in the future.
Keywords:
Bile acids, celiac disease, enzyme supplementation, gastrointestinal disease, lactose intolerance, pancreatic insufficiency.
Affiliation:
Department of Medical Sciences, Division of Internal Medicine, Gastroenterology and Liver Unit, Catholic University, School of Medicine and Surgery, A. Gemelli Hospital Rome, Italy, Largo A. Gemelli 8, IT-00168 Rome, Italy.
Read Full-Text article